Completed PHASE1 INTERVENTIONAL 2-arm NCT00965432

A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy, Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107

Sponsor: National Institutes of Health (NIH)

Conditions Fragile X Syndrome

Interventions STX107

Updated 6 times since 2017 Last updated: Feb 5, 2010 Started: Sep 30, 2009 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00965432, this PHASE1 trial focuses on Fragile X Syndrome and remains completed. Sponsored by National Institutes of Health (NIH), it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institutes of Health (NIH)
Seaside Therapeutics, Inc.

Data source: Seaside Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States